Aimmune Therapeutics Inc. (AIMT)’s Financial Results Comparing With Catalyst Biosciences Inc. (NASDAQ:CBIO)

This is a contrast between Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Catalyst Biosciences Inc. (NASDAQ:CBIO) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics Inc. 21 -0.17 36.95M -3.62 0.00
Catalyst Biosciences Inc. 6 0.06 7.14M -3.36 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 shows us Aimmune Therapeutics Inc. and Catalyst Biosciences Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics Inc. 172,261,072.26% -79.1% -66.4%
Catalyst Biosciences Inc. 116,666,666.67% -32.6% -31.5%

Risk and Volatility

Aimmune Therapeutics Inc. has a -0.11 beta, while its volatility is 111.00%, thus making it less volatile than S&P 500. Catalyst Biosciences Inc. on the other hand, has 1.88 beta which makes it 88.00% more volatile compared to S&P 500.


The Current Ratio of Aimmune Therapeutics Inc. is 7.6 while its Quick Ratio stands at 7.6. The Current Ratio of rival Catalyst Biosciences Inc. is 24.9 and its Quick Ratio is has 24.9. Catalyst Biosciences Inc. is better equipped to clear short and long-term obligations than Aimmune Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for Aimmune Therapeutics Inc. and Catalyst Biosciences Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aimmune Therapeutics Inc. 0 1 0 2.00
Catalyst Biosciences Inc. 0 0 0 0.00

Aimmune Therapeutics Inc.’s upside potential is 47.12% at a $33 average target price.

Institutional and Insider Ownership

The shares of both Aimmune Therapeutics Inc. and Catalyst Biosciences Inc. are owned by institutional investors at 86.3% and 82.9% respectively. Insiders held 0.6% of Aimmune Therapeutics Inc. shares. On the other hand, insiders held about 0.4% of Catalyst Biosciences Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aimmune Therapeutics Inc. 1.91% -9.03% -2.92% -15.79% -29.77% -19.52%
Catalyst Biosciences Inc. -1.92% 10.38% -5.43% -4.21% -15.39% 3.8%

For the past year Aimmune Therapeutics Inc. had bearish trend while Catalyst Biosciences Inc. had bullish trend.


On 6 of the 11 factors Catalyst Biosciences Inc. beats Aimmune Therapeutics Inc.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.